■2019年冠状病毒病(COVID-19)是由RNA病毒SARS-CoV-2引起的严重呼吸道疾病。全球范围内,超过7.594亿例,674万人死亡,而厄瓜多尔报告了超过106万例病例和35.9万人死亡。为了描述COVID-19在厄瓜多尔这样的低收入国家的大流行影响和疫苗接种效果,我们旨在评估CruzRojaEcuatoriana健康献血者样本中针对SARS-CoV-2的IgG和IgM抗体的血清阳性率.
■本血清阳性率研究使用侧流免疫分析法(LFIA)在确诊病例率最高的月份中检测抗SARS-CoV-2IgG和IgM抗体(2020年5月;1月,2021年4月;1月,二月,六月,2022年7月)和疫苗接种率最高的月份(5月,六月,七月,August,2021年12月)在基多,厄瓜多尔。IgG和IgM血清阳性率也根据性别进行评估,年龄范围,血型和RhD抗原类型。样本量为8,159,并根据每种血型的可用性进行采样。
■结果显示总体IgG和IgM血清阳性率分别为47.76%和3.44%,分别。血型和性别之间的IgG和IgM血清价值没有差异,而统计差异是基于月份发现的,年龄组,和RhD抗原类型。例如,在2022年2月和17-26岁年龄段中观察到最高的IgG血清阳性率,而IgM血清阳性率最高的是2021年4月和47-56岁年龄段人群.最后,RhD+个体中只有IgG血清阳性率较高,而不同RhD类型的IgM血清阳性率相似.
■该项目有助于厄瓜多尔针对SARS-CoV-2的IgG和IgM抗体的有限数据。这表明群体免疫可能是在过去评估的几个月中实现的,并强调了RhD抗原类型与COVID-19易感性之间的潜在联系。这些发现不仅对厄瓜多尔的公共卫生策略和疫苗分布有影响,而且对具有类似特征的地区也有影响。
UNASSIGNED: Coronavirus Disease 2019 (COVID-19) is a severe respiratory illness caused by the RNA virus SARS-CoV-2. Globally, there have been over 759.4 million cases and 6.74 million deaths, while Ecuador has reported more than 1.06 million cases and 35.9 thousand deaths. To describe the COVID-19 pandemic impact and the vaccinations effectiveness in a low-income country like Ecuador, we aim to assess the seroprevalence of
IgG and IgM antibodies against SARS-CoV-2 in a sample from healthy blood donors at the Cruz Roja Ecuatoriana.
UNASSIGNED: The present seroprevalence study used a lateral flow immunoassay (LFIA) to detect anti-SARS-CoV-2
IgG and IgM antibodies in months with the highest confirmed case rates (May 2020; January, April 2021; January, February, June, July 2022) and months with the highest vaccination rates (May, June, July, August, December 2021) in Quito, Ecuador. The
IgG and IgM seroprevalence were also assessed based on sex, age range, blood type and RhD antigen type. The sample size was 8,159, and sampling was performed based on the availability of each blood type.
UNASSIGNED: The results showed an overall
IgG and IgM seroprevalence of 47.76% and 3.44%, respectively. There were no differences in IgG and IgM seroprevalences between blood groups and sex, whereas statistical differences were found based on months, age range groups, and RhD antigen type. For instance, the highest
IgG seroprevalence was observed in February 2022 and within the 17-26 years age range group, while the highest IgM seroprevalence was in April 2021 and within the 47-56 years age range group. Lastly, only IgG seroprevalence was higher in RhD+ individuals while IgM seroprevalence was similar across RhD types.
UNASSIGNED: This project contributes to limited data on IgG and IgM antibodies against SARS-CoV-2 in Ecuador. It suggests that herd immunity may have been achieved in the last evaluated months, and highlights a potential link between the RhD antigen type and COVID-19 susceptibility. These findings have implications for public health strategies and vaccine distribution not only in Ecuador but also in regions with similar characteristics.